What's Coming Up on the Lung Cancer Treatment Horizon?
Non‑small‑cell lung cancer (NSCLC) treatment has changed a lot in recent years.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT